Resultats de la cerca - Laurent Greillier

Refinar resultats
  1. 1
    The clinical utility of tumor mutational burden in non-small cell lung cancer

    The clinical utility of tumor mutational burden in non-small cell lung cancer per Laurent Greillier, Pascale Tomasini, Fabrice Barlési

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  2. 2
    Ipilimumab: its potential in non-small cell lung cancer

    Ipilimumab: its potential in non-small cell lung cancer per Pascale Tomasini, Nataliya Khobta, Laurent Greillier, Fabrice Barlési

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

    Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes per Pascale Tomasini, Fabrice Barlési, Céline Mascaux, Laurent Greillier

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  4. 4
    Personalised medicine for nonsmall cell lung cancer

    Personalised medicine for nonsmall cell lung cancer per Céline Mascaux, Pascale Tomasini, Laurent Greillier, Fabrice Barlési

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  5. 5
    Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases

    Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases per Pascale Tomasini, Julie Egea, M. Souquet-Bressand, Laurent Greillier, Fabrice Barlési

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  6. 6
    Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma

    Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma per Laurent Greillier, A. Cavaillès, A. Fraticelli, Arnaud Scherpereel, Fabrice Barlési, Gianfranco Tassi, P. Thomas, Philippe Astoul

    Publicat 2007
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer

    Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer per Fabrice Barlési, Céline Gimenez, Jean-Philippe Torre, C. Doddoli, Julien Mancini, Laurent Greillier, François Roux, J P Kleisbauer

    Publicat 2003
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population

    EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderl... per Athanasios Pallis, Cesare Gridelli, Jan P. van Meerbeeck, Laurent Greillier, Ulrich Wedding, Didier Lacombe, John J. Welch, Chandra P. Belani, Matti Aapro

    Publicat 2009
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  9. 9
    EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer

    EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer per Pascale Tomasini, Cindy Serdjebi, Nataliya Khobta, Philippe Métellus, L’Houcine Ouafik, Isabelle Nanni, Laurent Greillier, Anderson Loundou, Frédéric Fina, Céline Mascaux, Fabrice Barlési

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer

    Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer per M. Grangeon, Pascale Tomasini, S. Chaléat, A. Jeanson, M. Souquet-Bressand, Nataliya Khobta, Julien Bermudez, Youssef Trigui, Laurent Greillier, M. Blanchon, Mohamed Boucékine, Céline Mascaux, Fabrice Barlési

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

    Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expre... per Clémence Demerle, Laurent Gorvel, Marielle Mello, Sonia Pastor, Clara Degos, Ana Zarubica, Fabien Angelis, Frédéric Di Fiore, Jacques A. Nunès, Bernard Malissen, Laurent Greillier, Geoffrey Guittard, Hervé Luche, Fabrice Barlési, Daniel Olive

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey

    Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cance... per Antonin Lévy, Corinne Faivre‐Finn, Baktiar Hasan, Eléonora De Maio, Anna S. Berghoff, Nicolas Girard, Laurent Greillier, Sylvie Lantuéjoul, Mary O’Brien, Martin Reck, Anne‐Marie C. Dingemans, Silvia Novello, Thierry Berghmans, Benjamin Besse, Lizza Hendriks

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

    Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC) per A. Jeanson, Pascale Tomasini, M. Souquet-Bressand, Nicolas Brandone, Mohamed Boucékine, M. Grangeon, S. Chaléat, Natalyia Khobta, Julie Milia, Laurent Mhanna, Laurent Greillier, Julie Biemar, Isabelle Nanni, L’Houcine Ouafik, Stéphane Garcia, Julien Mazières, Fabrice Barlési, Céline Mascaux

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

    Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY... per Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana‐Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC

    A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC per Jyoti Malhotra, Petros Nikolinakos, Ticiana Leal, Jonathan M. Lehman, Daniel Morgensztern, Jyoti D. Patel, John M. Wrangle, Giuseppe Curigliano, Laurent Greillier, Melissa L. Johnson, Neal Ready, G. Robinet, Satwant Lally, David Maag, Ricardo Santoyo Valenzuela, Vincent Blot, Benjamin Besse

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease

    EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease per Antonin Lévy, Lizza Hendriks, Thierry Berghmans, Corinne Faivre‐Finn, Matteo Giaj Levra, Niccolò Giaj-Levra, Baktiar Hasan, Alessia Pochesci, Nicolas Girard, Laurent Greillier, Sylvie Lantuéjoul, John Edwards, Mary O’Brien, Martin Reck, Benjamin Besse, Silvia Novello, Anne‐Marie C. Dingemans

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers

    EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers per Marco Tagliamento, Marie Morfouace, Charalambos Loizides, Júlio Oliveira, Laurent Greillier, Judith Raimbourg, Anne‐Claire Toffart, Thierry Chatellier, Nicolas Cloarec, Ivana Sullivan, Birute Brasiūnienė, M. Duruisseaux, Kersti Oselin, Marie-Sophie Robert, C. Fernandes, Arnaud Poncin, Jean‐Yves Blay, Benjamin Besse, Nicolas Girard

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial

    Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial per Olivier Bylicki, Florian Guisier, Arnaud Scherpereel, Catherine Daniel, Aurélie Swalduz, Emmanuel Grolleau, Massimo Bernardi, S. Hominal, Jean.Briac Prevost, G. Pamart, Marie.Héléne Marques, Nicolas Cloarec, S. Deshayes, Judith Raimbourg, Rémi Veillon, Youssef Oulkhouir, Clarisse Audigier-Valette, Fabien Subtil, C. Chouaïd, Laurent Greillier

    Publicat 2024
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

    Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio... per Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Julien Mazières, Sylvie Lantuéjoul, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, V. Gounant, Martine Antoine, Denis Moro‐Sibilot, Isabelle Rouquette, Olivier Molinier, R. Corre, Isabelle Monnet, Alexandra Langlais, Franck Morin, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

    First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 per Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, Thomas Talbot, I. Monnet, Sandrine Hiret, Paul Baas, Anna K. Nowak, Nobukazu Fujimoto, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, X. Zhang, Nan Hu, David Balli, Thomas E. Spires, Gérard Zalcman

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: